Division of Cardiology, Department of Medicine, The Mount Sinai Hospital, New York, USA.
Curr Opin Cardiol. 2020 Jul;35(4):313-318. doi: 10.1097/HCO.0000000000000750.
In recent years, no other field of cardiology has experienced a greater influx of transformational therapeutic options as valvular heart disease. The present review discusses the landmark trials published in the last 18 months that have shaped the modern day management of valvular heart diseases.
There have been several landmark trials in recent years, which have expanded the indications for transcatheter aortic valve replacement to low-risk surgical patients and the use of MitraClip for patients with functional mitral regurgitation. Options for transcatheter management of right-sided valvular disease also continue to evolve, including promising results from early feasibility studies.
The development of novel transcatheter therapies for valvular heart disease has expanded the armamentarium of physicians treating patients with valvular heart disease. The present review will focus on the recent (within 2 years) trials in this field of interest.
近年来,心血管领域没有哪个领域像心脏瓣膜病一样迎来了如此多的变革性治疗选择。本综述讨论了过去 18 个月中发布的具有里程碑意义的试验,这些试验塑造了当今心脏瓣膜病的治疗模式。
近年来有几项具有里程碑意义的试验,这些试验扩大了经导管主动脉瓣置换术的适应证,使其适用于低危手术患者,以及使用 MitraClip 治疗功能性二尖瓣反流患者。经导管治疗右心瓣膜疾病的选择也在不断发展,包括早期可行性研究的有希望的结果。
新型经导管治疗心脏瓣膜病的发展扩大了治疗心脏瓣膜病患者的医生的治疗手段。本综述将重点关注该领域最近(2 年内)的试验。